Eli Lilly & Co. vs. Rallybio Corporation Common Stock
Eli Lilly & Co. (LLY) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| LLY | RLYB | |
|---|---|---|
| Market Cap | $994.90 billion | $85.65 million |
| Revenue (TTM) | $65.18 billion | $858,000 |
| Net Income (TTM) | $20.64 billion | $-7,817,000 |
LLY leads on 3 of 3 size & scale factors.
Valuation
| LLY | RLYB | |
|---|---|---|
| P/E Ratio | 50.97 | — |
| Price / Book | 37.49 | 1.70 |
| Price / Sales | 15.26 | 99.83 |
LLY and RLYB split the valuation factors evenly.
Profitability
| LLY | RLYB | |
|---|---|---|
| Net Margin | 31.67% | -911.07% |
| Return on Equity | 77.78% | -15.55% |
LLY leads on 2 of 2 profitability factors.
Dividend
| LLY | RLYB | |
|---|---|---|
| Dividend Yield | 0.59% | — |
| Payout Ratio | 30.15 | — |
LLY and RLYB split the dividend factors evenly.
Risk & Sentiment
| LLY | RLYB | |
|---|---|---|
| Short Interest | 1.29% | 0.02% |
RLYB leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, RLYB overview, RLYB financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.